Sumatriptan: update and review

Abstract

Sumatriptan is the first of a novel class of medications referred to as triptans. Since its approval for migraine in the 1990s, six other triptan products have received FDA approval. Despite the proliferation of triptans, sumatriptan remains the most frequently prescribed product in this therapeutic class. Sumatriptan has been instrumental in defining a biological basis for migraine. It is effective in treating migraine with or without aura, well tolerated and, when properly prescribed, safe. Sumatriptan injection is the only member of the triptan class approved for treatment of cluster headache. Studies with sumatriptan have also advanced the therapeutic intervention paradigm that permits patients to treat earlier and avoid substantial disability. Numerous pharmacoeconomic studies have demonstrated that sumatriptan decreases work loss productivity and improves quality of life.

Keywords::

• migraine
• sumatriptan
• triptans

Disclaimer

C Schreiber has no financial interest with GlaxoSmithKline (GSK). R Cady has served on GSK advisory boards, in a consultant capacity and as a speaker on their behalf, and has received honoraria for these activites. RC has also conducted, and received grants/funding for clinical research trials for GSK.

Notes